Neosalus, formulated with Quinnova’s patented Proderm Technology, provides skin barrier repair, protection, and moisturization.
Christopher Hensby, senior vice president of Quinnova, said: “To treat recalcitrant skin conditions such as atopic dermatitis and hand eczema, a comprehensive and long term solution is required to address the underlying issue of a compromised skin barrier while reducing inflammation.
“First and foremost, Neosalus helps to restore a dysfunctional skin barrier by replenishing the lost lipids, thereby decreasing trans-epidermal water loss. Furthermore, Neosalus functions as a protectant to reduce the penetration of irritants from further exacerbating the itch and scratch cycle. Finally, Neosalus has anti-inflammatory ability that helps to reduce the frequency and severity of flare-ups, thus making it a steroid sparing and complementary treatment to other concomitant treatments.”